Literature DB >> 8280512

Anthracyclines and the heart.

W Rhoden1, P Hasleton, N Brooks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8280512      PMCID： PMC1025378          DOI： 10.1136/hrt.70.6.499

Source DB:  PubMed          Journal:  Br Heart J        ISSN： 0007-0769


× No keyword cloud information.
  50 in total

1.  Long term survival after heart transplantation for doxorubicin induced cardiomyopathy.

Authors:  M Aricò; E Pedroni; L Nespoli; M Viganò; F Porta; G R Burgio
Journal:  Arch Dis Child       Date:  1991-08       Impact factor: 3.791

2.  Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer.

Authors:  A M Goorin; A R Chauvenet; A R Perez-Atayde; J Cruz; R McKone; S E Lipshultz
Journal:  J Pediatr       Date:  1990-01       Impact factor: 4.406

3.  Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.

Authors:  L J Steinherz; T Graham; R Hurwitz; H M Sondheimer; R G Schwartz; E M Shaffer; G Sandor; L Benson; R Williams
Journal:  Pediatrics       Date:  1992-05       Impact factor: 7.124

4.  Functional myocardial impairment in children treated with anthracyclines for cancer.

Authors:  S T Yeung; C Yoong; J Spink; A Galbraith; P J Smith
Journal:  Lancet       Date:  1991-04-06       Impact factor: 79.321

5.  Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400 mg/m2: evidence for enhanced toxicity with multiagent chemotherapy.

Authors:  R G Watts
Journal:  Am J Hematol       Date:  1991-03       Impact factor: 10.047

6.  Cardiovascular autonomic function in anthracycline-treated breast cancer patients.

Authors:  M Viniegra; M Marchetti; M Losso; A Navigante; S Litovska; A Senderowicz; L Borghi; J Lebron; D Pujato; H Marrero
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute.

Authors:  G N Hortobagyi; A U Buzdar; C E Marcus; T L Smith
Journal:  NCI Monogr       Date:  1986

8.  Late, late doxorubicin cardiotoxicity.

Authors:  S L Gottlieb; W A Edmiston; L J Haywood
Journal:  Chest       Date:  1980-12       Impact factor: 9.410

9.  Radionuclide evaluation of doxorubicin cardiotoxicity: the need for cautious interpretation.

Authors:  H M Dey; H Kassamali
Journal:  Clin Nucl Med       Date:  1988-08       Impact factor: 7.794

10.  Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.

Authors:  M R Bristow; J W Mason; M E Billingham; J R Daniels
Journal:  Am Heart J       Date:  1981-10       Impact factor: 4.749
View more
  10 in total

1.  Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women.

Authors:  Y Cottin; C Touzery; B Coudert; S Richebourg; M Cohen; M Toubeau; P Louis; J E Wolf; F Brunotte
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2+) handling and contractile function in rat heart.

Authors:  R Zucchi; G Yu; S Ghelardoni; F Ronca; S Ronca-Testoni
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 3.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

4.  Anthracyclines and the heart.

Authors:  P Thomas
Journal:  Br Heart J       Date:  1994-09

Review 5.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

6.  Impairment of diastolic function during short-term anthracycline chemotherapy.

Authors:  Y Cottin; C Touzery; B Coudert; A Gilles; P Walker; J L Massing; M Toubeau; A Riedinger-Berriolo; D Caillot; P Louis
Journal:  Br Heart J       Date:  1995-01

7.  Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

8.  Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.

Authors:  H de Graaf; W V Dolsma; P H Willemse; W T van der Graaf; D T Sleijfer; E G de Vries; N H Mulder
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up.

Authors:  Olga Lenčová-Popelová; Eduard Jirkovský; Yvona Mazurová; Juraj Lenčo; Michaela Adamcová; Tomáš Šimůnek; Vladimír Geršl; Martin Štěrba
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

Review 10.  Rabbit models of heart disease.

Authors:  Steven M Pogwizd; Donald M Bers
Journal:  Drug Discov Today Dis Models       Date:  2009-03-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.